Skip to main content
SpringerLink
Log in

Comparisons of 131I-rituximab treatment responses in patients with aggressive lymphoma and indolent lymphoma

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

We evaluated the changes in treatment response over time after single 131I-rituximab radioimmunotherapy (RIT) according to non-Hodgkin lymphoma (NHL) types.

Methods

Fifteen aggressive and 21 indolent lymphoma cases undergoing RIT were evaluated. All patients underwent 18F-FDG-PET-CT before and 5 days, 1, and 3 months after RIT. The maximum standardized uptake value (SUV) and the sum of the products of the longest perpendicular diameters of tumours (SPD) were evaluated. Treatment responses were evaluated 1 and 3 months after RIT

Results

In aggressive lymphoma, SUV decreased at 5 days after RIT but increased after that. SPD decreased at 1 month but significantly increased at 3 months. Complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) at 1 month after RIT were changed to PD at 3 months after RIT. In indolent lymphoma, the SUV decreased continuously until 1 month after RIT. The SPD significantly decreased at 1 month and tended to further decrease to 3 months. CR, PR, SD, and PD at 1 month after RIT were achieved in 0, 8, 13, and 0 cases, respectively. Among the 13 SD cases, one changed to CR, three changed to PR, and nine had not changed at 3 months after RIT.

Conclusions

The treatment response to single RIT differed depending on NHL type. These findings suggest a need to establish an optimal treatment regimen based on NHL aggressiveness.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.

    Article  Google Scholar 

  2. England CG, Rui L, Cai W. Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies. Eur J Nucl Med Mol Imaging. 2017;44(3):517–32.

    Article  CAS  Google Scholar 

  3. Chiu BC, Hou N. Epidemiology and etiology of non-hodgkin lymphoma. Cancer Treat Res. 2015;165:1–25.

    Article  Google Scholar 

  4. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22(47):7359–68.

    Article  CAS  Google Scholar 

  5. Eskian M, Khorasanizadeh M, Zinzani PL, Rezaei N. Radioimmunotherapy as the first line of treatment in non-Hodgkin lymphoma. Immunotherapy. 2018;10(8):699–711.

    Article  CAS  Google Scholar 

  6. Leahy MF, Turner JH. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients. Blood. 2011;117(1):45–52.

    Article  CAS  Google Scholar 

  7. Kang HJ, Lee SS, Kim KM, Choi TH, Cheon GJ, Kim WS, et al. Radioimmunotherapy with 131I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL). Asia Pac J Clin Oncol. 2011;7(2):136–45.

    Article  Google Scholar 

  8. Kang HJ, Lee SS, Byun BH, Kim KM, Lim I, Choi CW, et al. Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma. Cancer Chemother Pharmacol. 2013;71(4):945–53.

    Article  CAS  Google Scholar 

  9. Eskian M, Khorasanizadeh M, Kraeber-Bodere F, Rezaei N. Radioimmunotherapy in non-Hodgkin lymphoma: prediction and assessment of response. Crit Rev Oncol Hematol. 2016;107:182–9.

    Article  Google Scholar 

  10. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–86.

    Article  Google Scholar 

  11. Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood. 2004;103(12):4429–31.

    Article  CAS  Google Scholar 

  12. Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, et al. Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96(4):1259–66.

    Article  CAS  Google Scholar 

  13. Leahy MF, Seymour JF, Hicks RJ, Turner JH. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol. 2006;24(27):4418–25.

    Article  CAS  Google Scholar 

  14. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005;16(9):1514–23.

    Article  CAS  Google Scholar 

  15. Takahashi M, Momose T, Koyama K, Ichikawa M, Kurokawa M, Ohtomo K. Dynamic metabolic changes during the first 3 months after 90Y-ibritumomab tiuxetan radioimmunotherapy. Sci World J. 2014;2014:368947.

    Google Scholar 

  16. DeNardo GL, Schlom J, Buchsbaum DJ, Meredith RF, O'Donoghue JA, Sgouros G, et al. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer. 2002;94(4 Suppl):1332–488.

    Article  CAS  Google Scholar 

  17. Morschhauser F, Kraeber-Bodéré F, Wegener WA, Harousseau J-L, Petillon M-O, Huglo D, et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. J Clin Oncol. 2010;28(23):3709–16.

    Article  CAS  Google Scholar 

  18. Illidge TM, Mayes S, Pettengell R, Bates AT, Bayne M, Radford JA, et al. Fractionated 90Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria. J Clin Oncol. 2014;32(3):212–8.

    Article  CAS  Google Scholar 

  19. Illidge TM, Bayne M, Brown NS, Chilton S, Cragg MS, Glennie MJ, et al. Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood. 2009;113(7):1412–21.

    Article  CAS  Google Scholar 

  20. Martínez A, Martínez-Ramirez M, Martínez-Caballero D, Beneit P, Clavel J, Figueroa G, et al. Radioimmunotherapy for non-Hodgkin's lymphoma: positioning, safety, and efficacy of 90Y-ibritumomab 10 years of experience and follow-up. Rev Esp Med Nucl Imagen Mol. 2017;36(1):13–9.

    PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by a grant from the Korea Institute of Radiological and Medical Science (KIRAMS), funded by the Ministry of Science and ICT of the Republic of Korea (Nos. 50330-2019, 50477-2019, and 50541-2019)

Funding

A grant from the Korea Institute of Radiological and Medical Science (KIRAMS), funded by the Ministry of Science and ICT of the Republic of Korea (Nos. 50330-2019, 50477-2019, and 50541-2019).

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, 75, Nowon-ro, Nowon-gu, Seoul, Korea

    Inki Lee, Byung Hyun Byun, Ilhan Lim, Byung Il Kim, Chang Woon Choi & Sang Moo Lim

  2. Division of Applied RI, Research Institute of Radiological and Medical Sciences, Korea Institutes of Radiological and Medical Sciences, Seoul, Korea

    Kyeong Min Kim

  3. Division of Hematology/Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, 75, Nowon-ro, Nowon-gu, Seoul, Korea

    Dong-Yeop Shin & Hye Jin Kang

Authors
  1. Inki Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Byung Hyun Byun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ilhan Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Byung Il Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chang Woon Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kyeong Min Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dong-Yeop Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hye Jin Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sang Moo Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Hye Jin Kang or Sang Moo Lim.

Ethics declarations

Conflict of interest

The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, I., Byun, B.H., Lim, I. et al. Comparisons of 131I-rituximab treatment responses in patients with aggressive lymphoma and indolent lymphoma. Ann Nucl Med 33, 881–890 (2019). https://doi.org/10.1007/s12149-019-01401-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-019-01401-5

Keywords

Search

Navigation